RxDoctor Payments DataLook up a doctor →

Jean Foucauld, MD

Cardiovascular Disease · Wellington, FLNPI 1164414900

Payments from drug & device makers

$3,471,289in general payments, 2019–2025

Across 817 payments — averaging $4248.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1.8M
  • Eli Lilly$777K
  • Janssen Research & Development, LLC$582K
  • Esperion Therapeutics, Inc.$130K
  • Bayer$122K
  • Sanofi US Services Inc.$38K
  • plus $51K from 33 others
$21,299in research payments, 2019–2025

Across 2 payments — averaging $10,649 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$21K

What the payments were for

  • Travel & lodging$5,37534%
  • Food & beverage$9,99663%
  • Education$4583%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,471,289 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$168,414
Medicare patients
289
Services billed
1,525

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban150$139,986
EntrestoSacubitril/Valsartan55$94,886
XareltoRivaroxaban76$71,095
Repatha SureclickEvolocumab29$36,394
JardianceEmpagliflozin13$17,760
FarxigaDapagliflozin Propanediol18$16,748
KerendiaFinerenone16$14,020
Repatha PushtronexEvolocumab12$10,874
VascepaIcosapent Ethyl19$6,535
Rosuvastatin Calcium262$4,536
Ranolazine ErRanolazine24$3,253
Nebivolol Hcl50$2,658
Olmesartan Medoxomil56$2,241
Metoprolol Succinate168$2,225
Ezetimibe86$1,692

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$165$139,986150 claims
NovartisEntresto$1,771,851$94,88655 claims
Johnson & JohnsonXarelto$398$71,09576 claims
Boehringer IngelheimJardiance$85$17,76013 claims
AstraZenecaFarxiga$610$16,74818 claims
BayerKerendia$122,092$14,02016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Wellington

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →